1. Home
  2. SHCO vs LQDA Comparison

SHCO vs LQDA Comparison

Compare SHCO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHCO
  • LQDA
  • Stock Information
  • Founded
  • SHCO 1995
  • LQDA 2004
  • Country
  • SHCO United Kingdom
  • LQDA United States
  • Employees
  • SHCO N/A
  • LQDA N/A
  • Industry
  • SHCO Hotels/Resorts
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHCO Consumer Discretionary
  • LQDA Health Care
  • Exchange
  • SHCO Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SHCO 1.7B
  • LQDA 1.9B
  • IPO Year
  • SHCO 2021
  • LQDA 2018
  • Fundamental
  • Price
  • SHCO $8.87
  • LQDA $24.22
  • Analyst Decision
  • SHCO Strong Buy
  • LQDA Strong Buy
  • Analyst Count
  • SHCO 1
  • LQDA 9
  • Target Price
  • SHCO $9.00
  • LQDA $32.67
  • AVG Volume (30 Days)
  • SHCO 328.5K
  • LQDA 2.9M
  • Earning Date
  • SHCO 08-08-2025
  • LQDA 11-12-2025
  • Dividend Yield
  • SHCO N/A
  • LQDA N/A
  • EPS Growth
  • SHCO N/A
  • LQDA N/A
  • EPS
  • SHCO N/A
  • LQDA N/A
  • Revenue
  • SHCO $1,251,591,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • SHCO $11.89
  • LQDA $405.58
  • Revenue Next Year
  • SHCO $7.87
  • LQDA $373.93
  • P/E Ratio
  • SHCO N/A
  • LQDA N/A
  • Revenue Growth
  • SHCO 9.00
  • LQDA 30.20
  • 52 Week Low
  • SHCO $4.60
  • LQDA $9.71
  • 52 Week High
  • SHCO $8.92
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • SHCO 73.44
  • LQDA 51.93
  • Support Level
  • SHCO $8.81
  • LQDA $21.35
  • Resistance Level
  • SHCO $8.87
  • LQDA $23.33
  • Average True Range (ATR)
  • SHCO 0.01
  • LQDA 1.19
  • MACD
  • SHCO -0.04
  • LQDA -0.07
  • Stochastic Oscillator
  • SHCO 75.00
  • LQDA 69.54

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: